These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35213233)

  • 1. Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification:
    Ng WT; Chua MLK; Lee AWM
    J Clin Oncol; 2022 Apr; 40(11):1135-1138. PubMed ID: 35213233
    [No Abstract]   [Full Text] [Related]  

  • 2. Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review.
    Xue F; He X
    Methods Mol Biol; 2020; 2204():99-107. PubMed ID: 32710318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma.
    Zong J; Ji P; Lin C; Zhang R; Chen Y; Lu Q; Peng X; Pan J; Lin S
    Oral Oncol; 2022 Aug; 131():105972. PubMed ID: 35728415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
    Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
    Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level.
    Liu SL; Sun XS; Xie HJ; Chen QY; Lin HX; Liang H; Liang YJ; Li XY; Yan JJ; Lin C; Yang ZC; Guo SS; Liu LT; Tang QN; Du YY; Tang LQ; Guo L; Mai HQ
    BMC Cancer; 2020 Feb; 20(1):89. PubMed ID: 32013967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
    Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Epstein-Barr virus DNA and SAA with S1 maintenance therapy outcomes in patients with metastatic nasopharyngeal carcinoma.
    Lu Y; Jiang Z; Lin H; Yang H; Chen X; Huang H
    Future Oncol; 2022 Jul; 18(22):2441-2451. PubMed ID: 35678594
    [No Abstract]   [Full Text] [Related]  

  • 8. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
    Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of prognostic value of Raf kinase inhibitory protein and pretreatment plasma Epstein-Barr virus DNA for distant metastasis in locoregionally advanced nasopharyngeal carcinoma.
    Li SW; Wang H; Xiang YQ; Zhang HB; Lv X; Xia WX; Zeng MS; Mai HQ; Hong MH; Guo X
    Head Neck; 2013 Apr; 35(4):579-91. PubMed ID: 22605662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
    Fung SY; Lam JW; Chan KC
    Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of adding systemic inflammation response index to Epstein-Barr virus DNA in childhood nasopharyngeal carcinoma: A real-world study.
    Jin YN; Liu BQ; Peng KW; Ou XQ; Zeng WS; Zhang WJ; Marks T; Yao JJ; Xia LP
    Head Neck; 2022 Jun; 44(6):1404-1413. PubMed ID: 35373866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress and controversy for the role of chemotherapy in nasopharyngeal carcinoma.
    Yoshizaki T; Kondo S; Murono S; Endo K; Tsuji A; Nakanishi Y; Nakanishi S; Sugimoto H; Hatano M; Ueno T; Wakisaka N
    Jpn J Clin Oncol; 2015 Mar; 45(3):244-7. PubMed ID: 25583421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Clinical Value of Plasma Epstein-Barr Virus DNA as a Tumor Marker in Nasopharyngeal Carcinoma: Prognostic? Yes, But How Can We Best Use It?
    Dragovic AF
    Cancer J; 2022 Mar-Apr 01; 28(2):93-95. PubMed ID: 35333491
    [No Abstract]   [Full Text] [Related]  

  • 14. [Diagnostics of nasopharyngeal carcinoma with Epstein-Barr virus (Herpesviridae, Lymphocryptovirus, HHV-4) serological and molecular markers in cases of undetected primary tumor location.].
    Senyuta NB; Smirnova KV; Kondratova VN; Ignatova AV; Mudunov AM; Dushenkina TE; Liechtenstein AV; Gurtsevich VE
    Vopr Virusol; 2019; 64(5):229-237. PubMed ID: 32167688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma.
    Huang CL; Sun ZQ; Guo R; Liu X; Mao YP; Peng H; Tian L; Lin AH; Li L; Shao JY; Sun Y; Ma J; Tang LL
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):355-361. PubMed ID: 30682489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.
    Li W; Chen J; Liang B; Li Z; Li J; Yuan X; Wu S; Zeng F; Peng X; Li Y; Lu J; Zhao F; Liu X
    Cancer Med; 2021 Feb; 10(3):883-894. PubMed ID: 33378109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial.
    Tang SQ; Chen L; Li WF; Chan ATC; Huang SH; Chua MLK; O'Sullivan B; Lee AWM; Lee NY; Zhang Y; Chen YP; Xu C; Sun Y; Tang LL; Ma J
    Radiother Oncol; 2022 Feb; 167():179-186. PubMed ID: 34971660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus DNA detection by targeted sequencing in post-treatment plasma samples and prognosis of locally advanced nasopharyngeal cancer: implications for clinical research.
    Economopoulou P; Lianidou E; Psyrri A
    Ann Oncol; 2022 Aug; 33(8):747-749. PubMed ID: 35598800
    [No Abstract]   [Full Text] [Related]  

  • 19. Development and validation of a joint model for dynamic prediction of overall survival in nasopharyngeal carcinoma based on longitudinal post-treatment plasma cell-free Epstein-Barr virus DNA load.
    Zhu GL; Fang XL; Yang KB; Tang LL; Ma J
    Oral Oncol; 2022 Nov; 134():106140. PubMed ID: 36183501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of oral maintenance chemotherapy and predictive value of circulating EBV DNA in metastatic nasopharyngeal carcinoma.
    Zhou H; Lu T; Guo Q; Chen Y; Chen M; Chen Y; Lin Y; Chen C; Ma L; Xu Y; Lin S; Pan J
    Cancer Med; 2020 Apr; 9(8):2732-2741. PubMed ID: 32090498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.